Ammenheuser M M, Au W W, Whorton E B, Belli J A, Ward J B
Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston 77550.
Environ Mol Mutagen. 1991;18(2):126-35. doi: 10.1002/em.2850180208.
The autoradiographic 6-thioguanine-resistant mutant lymphocyte assay and a chromosome aberration assay were used to determine the time-course of appearance and persistence of elevated frequencies of hprt variants and dicentric chromosomes in patients receiving x-irradiation therapy. Twelve cancer patients, treated with 180-200 cGy/day, 5 days/wk, for 3-7 wk, were studied before treatment, at various weekly intervals during treatment, and after treatment. The hprt mutation assays were done with frozen/thawed lymphocytes isolated from aliquots of the same blood samples used for the chromosome aberration assays. The hprt variant frequencies (Vfs) of only 4 of the 7 patients assayed at 2 wk of treatment were elevated over pre-treatment Vfs, but during the 3rd and 4th weeks of treatment there were significant (P less than 0.01) 5- to 15-fold increases in all Vfs. By 6-32 wk after treatment Vfs had fallen to levels only slightly higher than the mean pre-treatment Vf. The frequencies of cells with dicentric chromosomes were significantly increased (P less than 0.01) after 1 wk of radiotherapy, continued to increase during therapy, and remained elevated after treatment. Five multiple sclerosis patients were also studied before and at 2 and 4 wk intervals after treatment with monthly i.v. doses of 750 mg/m2 of cyclophosphamide (CP). There were no significant elevations in chromosome aberrations at these post-treatment sample times. Previous assays for hprt mutants, done with aloquots of the same blood samples (Ammenheuser et al.: Mutat Res 204:509-520, 1988), had shown 8- to 20-fold increases in Vfs 2 wk after the 1st CP treatment. Our results demonstrate the complementary nature of these two human monitoring assays and emphasize the importance of careful selection of optimal sampling times.
采用放射自显影6 - 硫鸟嘌呤抗性突变淋巴细胞检测法和染色体畸变检测法,来确定接受X射线放射治疗患者体内次黄嘌呤 - 鸟嘌呤磷酸核糖转移酶(hprt)变体和双着丝粒染色体频率升高出现的时间进程及其持续情况。12例癌症患者接受了每周5天、每天180 - 200厘戈瑞(cGy)、为期3 - 7周的治疗,在治疗前、治疗期间不同的每周时间点以及治疗后均进行了研究。hprt突变检测是用从用于染色体畸变检测的相同血样等分试样中分离出的冻融淋巴细胞进行的。在治疗2周时检测的7例患者中,只有4例的hprt变体频率(Vfs)高于治疗前的Vfs,但在治疗第3周和第4周期间,所有Vfs均有显著(P小于0.01)的5至15倍增加。治疗后6至32周,Vfs降至仅略高于治疗前平均Vf的水平。放射治疗1周后,具有双着丝粒染色体的细胞频率显著增加(P小于0.01),在治疗期间持续增加,且治疗后仍保持升高。还对5例多发性硬化症患者在每月静脉注射750毫克/平方米环磷酰胺(CP)治疗前以及治疗后2周和4周的时间间隔进行了研究。在这些治疗后的采样时间点,染色体畸变没有显著升高。之前用相同血样等分试样进行的hprt突变体检测(阿姆门赫泽等人:《突变研究》204:509 - 520,1988年)显示,首次CP治疗后2周,Vfs增加了8至20倍。我们的结果证明了这两种人体监测检测方法的互补性,并强调了仔细选择最佳采样时间的重要性。